Figure 2 from Activation of Cell-Intrinsic Signaling in CAR-T Cells via a Chimeric IL7R Domain

T cells with IL7 pathway activation expand and circulate in vivo. A, Schematic of experimental design. NSG mice were injected on day 0 with 107 T cells expressing a ffLuc reporter. BLI was conducted biweekly, and peripheral blood collected on days 15 and 30. One group of mice was treated with ffLuc-only–modified T cells and intraperitoneal injections of IL7 daily from day 1 to 21. B, BLI monitoring T-cell expansion. C, Quantified radiance per mouse. Thick solid line, median BLI; dotted lines, individual values per mouse. D, Calculated doubling time of T-cell products with 95% confidence interval represented. E, T cells (CD3+GFP+) detected in peripheral blood on days 15 and 30 after injection. Thick solid line, median; dotted lines, individual values per mouse. Comparison between treatment cohorts on day 30 vs. no treatment: *, P P F, Concentration of human IL7 in murine plasma detected with ELISA. For the intraperitoneally injected mice on day 15, blood was collected 1 hour after IL7 injection. (n = 5 mice per group). hIL7, human IL7; NSG, NOD/SCIDγ; NT, nontransduced; PB, peripheral blood.